Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options

Abstract

Type 2 diabetes mellitus is known to increase the risk of the development of heart failure with preserved ejection fraction and worsen its symptoms. To date, no specific treatment has been shown to reduce morbidity and mortality in patients with heart failure with preserved ejection fraction. In this review, the authors summarized the existing evidence on how diabetes mellitus can promote the development and progression of heart failure with preserved ejection fraction. The authors also addressed medications including experimental ones that can potentially be beneficial in patients of this group.

Keywords

• heart failure with preserved ejection fraction
• hfpef
• diabetes mellitus
• sglt2 inhibitors
• review